Shenzhen People's Hospital
Shenzhen People's Hospital
Shenzhen, Guangdong, China25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo | NonSegmental Vitiligo | Not yet recruiting | Phase 3 | 2026-10-08 | NCT07865312 | |
| To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 2 | 2026-09-17 | NCT07447986 | |
| A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE | Non-cystic Fibrosis Bronchiectasis | Active, not recruiting | Not stated | 2026-09-08 | NCT07245407 | |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-07-14 | NCT07416474 | |
| Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-06-23 | NCT07663253 | |
| Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-05-22 | NCT06551220 | |
| Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Immune-related Pneumonia; Radiation-induced Lung Injury | Recruiting | Phase 2 / Phase 3 | 2026-04-22 | NCT07388680 | |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Recruiting | Phase 3 | 2026-04-07 | NCT07515079 | |
| Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne | Acneiform Eruptions, Skin and Connective Tissue Diseases, acne, sebaceous gland disorder, skin disorder | Recruiting | Phase 2 | 2026-04-06 | NCT07366229 | |
| Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 2 | 2026-04-01 | NCT07370519 | |
| Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis | Aortic Arch Syndromes, Skin and Connective Tissue Diseases, Takayasu arteritis, aortic disorder, arteritis, cardiovascular disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Not yet recruiting | Phase 4 | 2026-03-05 | NCT07451665 | |
| Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Recruiting | Phase 2 | 2025-12-24 | NCT07194200 | |
| A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, atrial septal defect, cardiovascular disorder, congenital heart disease, heart disorder, heart failure, heart septal defect, heart valve disorder, hypertensive disorder, lung disorder, pulmonary hypertension, respiratory system disorder, tricuspid valve insufficiency, vascular disorder | Not yet recruiting | Not stated | 2025-12-18 | NCT07292896 | |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-12-16 | NCT05799287 | |
| Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2025-09-26 | NCT04582136 | |
| Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants | Healthy Participants | Recruiting | Phase 4 | 2025-09-16 | NCT07174830 | |
| A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia | Genital Diseases, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Not yet recruiting | Phase 3 | 2025-08-28 | NCT07146386 | |
| A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography | cardiovascular disorder | Recruiting | Not stated | 2025-08-21 | NCT07133516 | |
| To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects | Pharmacokinetics | Active, not recruiting | Phase 1 | 2025-06-22 | NCT07030504 | |
| Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-04-03 | NCT06760039 | |
| PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2025-02-05 | NCT05033392 | |
| Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Not applicable | 2024-11-29 | NCT06709274 | |
| Long-term Efficacy and Safety Study of GV-971 | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 4 | 2024-11-15 | NCT05181475 | |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2024-10-22 | NCT06647940 | |
| Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2022-09-30 | NCT04263298 |